We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams.
Our business in numbers
Unless stated all financials at 31 December 2024
Portfolio companies
Value of life science portfolio
Capital pool
Members of the team
Investment team with PhDs
Portfolio company Board seats
A vision to unlock the potential from truly innovative science to transform patients’ lives
We do this by creating, building and scaling companies to turn exceptional science into transformational treatments to patients in areas of high unmet need.
A multidisciplinary team
The life sciences investment team members have deep technical scientific backgrounds, supplemented by strong commercial experience ranging from venture capital investment to pharmaceutical launch.
Supporting UK life science
The UK has a thriving life sciences industry and world-class research infrastructure. Syncona is committed to supporting this via its work with academics, its portfolio companies, and co-investors, as well as through its membership of the BioIndustry Association (BIA), the voice of the life sciences and biotech industry in the UK.
